Publishing House SB RAS:

Publishing House SB RAS:

Address of the Publishing House SB RAS:
Morskoy pr. 2, 630090 Novosibirsk, Russia



Advanced Search

The journal "Ateroskleroz"

2018 year, number 2

N-TERMINAL PRO-BRAN OF NATRIURETHETIC PEPTIDE AND STIMULATING FACTOR OF GROWTH OF ST-2 IN PATIENTS WITH ACUTE MYOCARDIAL INFRACTION DEPENDING ON EMISSION FACTION

E.V. Khorolets
Rostov State Medical Universaty, 344022, Rostov-on-Don, Nakhichevansky Lane, 29
Keywords: инфаркт миокарда, сердечная недостаточность, ST-2, NTproBNP, myocardial infraction, heart failure, ST-2, NTproBNP

Abstract

The aim of the study was to evaluate the markers of the prognosis of heart failure NTproBNP and ST-2 in the dynamics of inpatient treatment of patients with acute myocardial infarction with ST segment elevation (STEMI), depending on the ejection fraction (EF). Materials and methods. Clinical and laboratory characteristics of patients with STEMI ( n = 150) were studied depending on left ventricular (LV) LV EF < 50 % and FV ³ 50 %. The level of NTproBNP and ST-2 was assessed during hospitalization and discharge of patients. The GRACE scale calculated the prognosis of hospital mortality of patients with STEMI. Results. Middle-aged STEMI patients 61.7 ± 2.96 years had a high risk of mortality on the GRACE scale. The first day of the disease revealed an increase in the level of NTproBNP and ST-2. Patients with EF <50 % showed an increase in the studied indicators and markers of myocardial necrosis in comparison with EF> 50 %. In the dynamics of hospital treatment in patients with STEMI with an EF <50 %, high values of NTproBNP and ST-2 persisted; in contrast to patients with EF ³ 50 % a statistically significant decrease in NTproBNP and a decrease in ST-2 to normal values were established. Conclusion Laboratory indicators NTproBNP and ST-2 are markers of progression of heart failure in patients with STEMI at the hospital stage of treatment. In patients with STEMI with an EF <50 %, high values of NTproBNP and ST-2 persist throughout the in-patient treatment, determining the prognosis of heart failure.